Cargando…
Safety of Immunomodulatory Systemic Therapies Used in the Management of Immune-Related Cutaneous Adverse Events
Immune-related cutaneous adverse events (ircAEs) commonly occur in patients on treatment with immune checkpoint inhibitors and can significantly reduce patient quality of life. These are often treated with immunomodulatory agents, including glucocorticoids, immunosuppressants, and biologics. While o...
Autores principales: | Gu, Stephanie L., Nath, Sandy, Markova, Alina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674388/ https://www.ncbi.nlm.nih.gov/pubmed/38004475 http://dx.doi.org/10.3390/ph16111610 |
Ejemplares similares
-
Management of immune-related cutaneous adverse events with dupilumab
por: Kuo, Alyce Mei-Shiuan, et al.
Publicado: (2023) -
High Grade Dermatologic Adverse Events Associated With Immune Checkpoint Blockade for Cancer
por: Kuo, Alyce M., et al.
Publicado: (2022) -
IL12/23 Blockade with Ustekinumab as a Treatment for Immune-Related Cutaneous Adverse Events
por: Gu, Stephanie L., et al.
Publicado: (2023) -
The Clinical and Histopathological Features of Cutaneous Immune-Related Adverse Events and Their Outcomes
por: Hashimoto, Hiroki, et al.
Publicado: (2021) -
Characterization and Prognostic Significance of Cutaneous Immune-Related Adverse Events in Indian Patients on Immune Checkpoint Inhibitor Therapy
por: Duraisamy, Prasanna, et al.
Publicado: (2023)